A Phase II/III Study of KN026 Combined Chemotherapy With or Without Enlonstobart as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Gastric Cancer.

This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.

Start Date30 Dec 2025

Sponsor / Collaborator

Shanghai JMT Biological Technology Co Ltd

NCT06998771

/ Not yet recruitingPhase 2

A Phase II Trial to Evaluate the Safety and Efficacy of JSKN003 Combination Therapy as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Gastric Cancer or Resectable Gastric Cancer

This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.

Start Date15 Jun 2025

Sponsor / Collaborator

Shanghai JMT Biological Technology Co Ltd

NCT06747338

/ RecruitingPhase 3

A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.

This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive breast cancer.

Start Date16 Dec 2024

Sponsor / Collaborator

Shanghai JMT Biological Technology Co Ltd

100 Clinical Results associated with Anbenitamab

100 Translational Medicine associated with Anbenitamab

100 Patents (Medical) associated with Anbenitamab

Literatures (Medical) associated with Anbenitamab

20 Feb 2026·BRITISH JOURNAL OF CANCER

Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer

Article

Author: Zhang, Qingyuan ; Zhao, Wenhui ; Luo, Haitao ; Tang, Dabei ; Song, Ying ; Wang, Jingxuan ; Ma, Jianli ; Deng, Yuwei ; Liu, Xuhui ; Li, Liru ; Tang, Xiaowen ; Sun, Shengnan

BACKGROUND:

KN026 is a novel bispecific HER2-targeting antibody for HER2-positive recurrent or metastatic breast cancer that showed prolonged median PFS and lessened distinction of PFS regarding the HR subgroup in our phase II clinical trial, compared with PUFFIN study of first-line trastuzumab combined with pertuzumab therapy. A more detailed discovery of its peculiarity is needed for optimal application of KN026 treatment.

METHODS:

We performed whole-transcriptome sequencing of digital spatial profiling (DSP) on 8 pre/post-treatment tumor samples. Mechanistic explorations were conducted by plasmid transfection, co-culture, CCK8 proliferation assay and flow cytometry.

RESULTS:

Compared to the tumor regions with non-objective response (OR), those with OR had high expression of CALML5, TFAP2B, and ERBB2, and relatively low expression of ESR1 in tumor cells at baseline. The expression of ESR1 had a tentative association with PI3K/AKT and NOTCH signaling pathways which were downstream or interactive pathways of HER2 target and also acted as interactive pathways of ER-mediated signaling. The co-expression of ERBB2 and CDK12 emerged as a distinctive signature of OR. KN026 treatment also reshaped intratumoral activated T- and B-cell subtypes in hot-tumor regions, regardless of myeloid-derived cells.

CONCLUSIONS:

Both HER2 and ESR1 are determinant of KN026 efficacy in advanced HER2-positive breast cancer, implying the potential of KN026 combined with endocrine therapy in HER2- and ER-positive breast cancer.

01 Jan 2026·ANNALS OF ONCOLOGY

Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial

Article

Author: Liu, R ; Liu, Z ; Wu, X ; Li, Z ; Qin, Y ; Chen, Y ; She, L ; Ba, Y ; Liu, B ; Hou, X ; Li, S ; Xu, J ; Xie, Y ; Zhang, R ; Ning, F ; Deng, T ; An, Y ; Huang, M ; Liu, Y ; Zhao, J ; Du, Y ; Liu, Y P ; Zhang, H ; Yang, M ; Zou, K ; Qu, Y ; Yang, H ; Liu, C

BACKGROUND:

Gastric cancer after progression on trastuzumab treatment remains an unmet therapeutic challenge and is associated with suboptimal progression-free survival (PFS) and overall survival (OS).

PATIENTS AND METHODS:

This multicentre, randomised, double-blind, phase 3 trial was conducted at 51 hospital sites in China. Patients with HER2-positive gastric cancer or gastro-oesophageal junction (GC/GEJ) adenocarcinoma whose previous therapy containing trastuzumab had failed were randomised (1:1) to receive anbenitamab 30 mg/kg or placebo every 3 weeks, in combination with chemotherapy (paclitaxel 175 mg/m² or docetaxel 75 mg/m² on day 1 of a 21-day cycle, or irinotecan 125 mg/m² on day 1 and 8 of a 21-day cycle), stratified by combined chemotherapy (taxane [paclitaxel or docetaxel] or irinotecan), HER2 expression (IHC 3+ or IHC 2+/FISH+), and previous lines of therapy (1 or ≥2). Primary endpoints were independent review committee-assessed PFS and OS in the intention-to-treat population. This interim analysis was planned when approximate 120 PFS events were observed.

RESULTS:

A total of 188 patients were enrolled and assigned to receive anbenitamab plus chemotherapy (anbenitamab group, n=95) or chemotherapy alone (control group, n=93). At the prespecified interim analysis, anbenitamab plus chemotherapy significantly improved PFS (median [95% confidence interval (CI)], 7.1 [5.5-10.3] vs 2.7 [1.5-3.0] months; hazard ratio [HR], 0.25; 95% CI, 0.17-0.39; p<0.0001) and OS (median [95% CI], 19.6 [15.0-not evaluable] vs 11.5 [6.5-14.4] months; HR, 0.29; 95% CI, 0.17-0.50; p<0.0001) compared with chemotherapy alone. Grade 3 or higher treatment-related adverse events occurred in 56 (60%) of 94 patients who received anbenitamab plus chemotherapy and 42 (45%) of 93 patients who received chemotherapy alone, with neutropenia (30% vs 22%) and leukopenia (21% vs 25%) being most common. Treatment-related deaths were reported in 0 and 5 patients in the anbenitamab and control groups, respectively.

CONCLUSIONS:

Compared with chemotherapy alone, anbenitamab plus chemotherapy demonstrated clinically meaningful superior PFS and OS in patients with HER2-positive GC/GEJ adenocarcinoma whose previous therapy containing trastuzumab had failed. These findings warrant confirmation in the final analysis.

31 Dec 2025·mAbs

Antibodies to watch in 2025

Review

Author: Kapoor, Vaishali ; Crescioli, Silvia ; Kaplon, Hélène ; Visweswaraiah, Jyothsna ; Reichert, Janice M. ; Wang, Lin

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025. In particular, we report on 21 antibody therapeutics granted a first approval in at least one country or region during 2024, including bispecific antibodies tarlatamab (IMDELLTRA®), zanidatamab (Ziihera®), zenocutuzumab (BIZENGRI®), odronextamab (Ordspono®), ivonescimab (®), and antibody-drug conjugate (ADC) sacituzumab tirumotecan (®). We also discuss 30 investigational antibody therapeutics for which marketing applications were undergoing review by at least one regulatory agency, as of our last update on December 9, 2024, including ADCs datopotamab deruxtecan, telisotuzumab vedotin, patritumab deruxtecan, trastuzumab botidotin, becotatug vedotin, and trastuzumab rezetecan. Of 178 antibody therapeutics we include in the late-stage pipeline, we summarize key data for 18 for which marketing applications may be submitted by the end of 2025, such as bi- or multispecific antibodies denecimig, sonelokimab, erfonrilimab, and anbenitamab. Key trends in the development and approval of antibody formats such as bispecifics and ADCs, as well as clinical-phase transition and global approval success rates for these antibody formats, are reported.

News (Medical) associated with Anbenitamab

28 Oct 2025

·www.drugs.com

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC

Suzhou, China, October 28, 2025 - Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (PROC), not restricted by HER2 expression. This marks another accelerated review recognition for JSKN003 from an internationally authoritative regulatory agency, following two previous Breakthrough Therapy Designations from the National Medical Products Administration (NMPA) for both PROC and colorectal cancer (CRC) and an Orphan Drug Designation from the FDA for gastric cancer/gastroesophageal junction cancer (GC/GEJ) this year. As a significant milestone in its global development progress, this achievement fully validates the drug's substantial clinical potential and market prospects. Ovarian cancer (OC) is one of the most common malignant tumors of the female reproductive system. Most patients are diagnosed at an advanced stage, and the disease is characterized by a high recurrence rate and significant treatment challenges. The standard treatment regimens recommended by authoritative guidelines both domestically and internationally include surgery combined with platinum-based chemotherapy and targeted therapy maintenance. However, about 80% of OC cases recur, and eventually progress to PROC, leaving patients with limited effective treatment options and poor prognosis. The U.S. National Comprehensive Cancer Network (NCCN) recommended single-agent non-platinum chemotherapy with or without bevacizumab as preferred regimens for PROC. However, these non-platinum chemotherapies demonstrate limited efficacy, with the objective response rate (ORR) of only 10% to 15%, a median progression-free survival (mPFS) of only 3 to 4 months, and a median overall survival (OS) of approximately 12 months, highlighting an urgent need for new treatment options. The grant of FTD is based on the promising clinical data of JSKN003. The Company has presented a pooled analysis of the phase I clinical study in Australia (JSKN003-101, NCT05494918) and the phase I/II clinical study in China (JSKN003-102, NCT05744427) at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO). As of February 28, 2025, 46 patients with PROC, including 21 patients (45.7%) with HER2 IHC 0 and 18 patients (39.1%) with HER2 IHC 1+, 2+, 3+, were enrolled. Among all 46 patients, the ORR was 63.0%, the median PFS was 7.7 months. In patients with HER2 IHC 1+, 2+ and 3+, the ORR was 72.2%, the median PFS was 9.4 months. JSKN003 demonstrated robust PFS improvement in PROC, and the efficacy was observed across different HER2 expression subgroups. The Phase III clinical study of JSKN003 for PROC is currently underway in China, while a Phase II study has been approved to initiate in the U.S. The granting of FTD by the FDA will further accelerate the clinical development and regulatory review process of JSKN003, offering new hope to global patients with PROC who face limited treatment options. About JSKN003 JSKN003 is developed by site-specific conjugation to the Fc glycans of anbenitamab, resulting in a homogeneous and stable ADC with a DAR of 4. JSKN003 binds to two HER2 epitopes on tumor cells and release topoisomerase I inhibitors through cellular endocytosis, exerting anti-tumor effects. Compared to similar ADCs, JSKN003 demonstrates better serum stability, reduced hematological toxicity, and stronger tumor inhibition and bystander effect, resulting in significantly wider therapeutic window. Multiple registrational studies of JSKN003 are ongoing, including trials in HER2-positive breast cancer (BC), all-comer platinum-resistant ovarian cancer (PROC), HER2-low BC, and HER2-positive colorectal cancer (CRC). JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for gastric cancer (GC) and gastroesophageal junction cancer (GEJ); It has been granted two Breakthrough Therapy Designations by the National Medical Products Administration (NMPA) for platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer and HER2-positive advanced CRC that has failed prior oxaliplatin, fluorouracil, and irinotecan therapy. In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK). JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for tumor-related indications in mainland China (excluding Hong Kong, Macau or Taiwan). Alphamab retains exclusive production rights for JSKN003. About Alphamab Oncology Alphamab Oncology is an innovative biopharmaceutical company focused on oncology. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 9966.HK). Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations-the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies. One product has received market approval: Envafolimab (KN035, brand name: 恩维达 ® ), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide. Alphamab Oncology Forward-Looking Statements This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise. Pharmaceutical Information Statements Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement. Source: Alphamab Oncology

Clinical ResultLicense out/inOrphan DrugFast TrackASCO

14 Jul 2020

·www.biospace.com

Sanofi and MD Anderson Enter 5-Year Immuno-Oncology Alliance

Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments. Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments. It will leverage MD Anderson’s clinical trials infrastructure and Sanofi’s cancer pipeline. This is yet another example of Sanofi’s increased investment in the cancer space. On July 8, Sanofi licensed a previously undisclosed K-NK0004 program from The Netherlands-based Kiadis Pharma in a deal just shy of $1 billion. The deal covered Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies. In early June, Sanofi (China) Investment Co. signed a collaboration deal with Alphamab Oncology, based in Suzhou, China, to advance clinical trials of Alphamab’s KN-26 with Sanofi’s Taxotere (docetaxel) in HER2+ breast cancer. Jiangsu Alphamab Biopharmaceuticals Co., a wholly owned subsidiary of Alphamab Oncology, made the deal to advance clinical trials of the combination of KN026, an anti-HER2 bispecific antibody, and Sanofi’s Taxotere in HER2+ breast cancer. “Our goal is to improve the outcome for patients with a range of difficult-to-treat cancers, which is best achieved through a deep understanding of how investigational new drugs work,” said Peter Adamson, Global Development Head, Oncology and Pediatric Innovation at Sanofi. “This alliance leverages MD Anderson’s agile approach to early phase clinical trials, their laboratory capabilities and broad scientific expertise.” He added, “This will get us to go/no-go decisions much faster and help us identify potential new combinations and indications more accurately. That will save precious time and help us expand the spectrum of patients who could potentially benefit from our therapies.” MD Anderson oversees one of the largest cancer clinical trial programs in the U.S., which includes platforms for tissue collection, molecular and immune profiling and data analysis. This allows for full coverage of clinical trials from the time cancer biopsies are made, through and after treatment. “Not only do clinical trials help us to advance life-saving new treatments for our patients in need, they provide us with valuable information to understand which therapies may be more effective for which patients,” said Funda Meric-Bernstam, chair of Investigational Cancer Therapeutics at MD Anderson. “We are pleased to collaborate with Sanofi in this effort to accelerate the development of a pipeline of innovative cancer therapies.” The pact will also offer support of clinical trials for extra indications and drug combinations that are already being conducted at MD Anderson. The two organizations will collaboration on trial design, as well as usage of biomarker tests and assays. The partnership is expected to launch its first studies together this summer. “MD Anderson’s expertise in deep immune phenotyping and molecular profiling will provide invaluable insights into our emerging immunotherapy assets, helping us refine our selection of indications and explore new avenues,” said Dmitri Wiederschain, Global Head of Immuno-Oncology Research at Sanofi. “The knowledge we gain in this collaboration will also deepen our shared understanding of cancers’ potential vulnerabilities.” In early June, Sanofi’s chief executive officer, Paul Hudson, presented an overview of the company’s oncology strategy. Its strategy is focused on four core therapeutic areas in cancer, including multiple myeloma, skin, lung, and breast cancers. He indicated that its four anchor oncology therapies include Sarclisa, an anti-CD38 monoclonal antibody and Libtayo (cemiplimab-nwlc), a PD-1 checkpoint inhibitor, and pipeline programs that include an investigational anti-CEACAM 5 antibody drug conjugate and SERD (‘859), an oral selective estrogen receptor degrader. “We are rapidly building momentum with the execution of our oncology strategy, with several developments on both our pipeline and marketed treatments,” said Hudson. “Additionally, we are assembling a world-class development and marketing team to support our growth in this core area. We believe our efforts and treatments have the potential to make a significant difference in the lives of people living with cancer.”

ImmunotherapyLicense out/in

17 Jul 2019

·endpts.com

Following footsteps of chart-topping Chinese counterparts, Alphamab Oncology files IPO at HKEX

Less than two months after raising $60 million — its second venture round in a decade — Alphamab is making the hop for the public markets. In its IPO filing with the Hong Kong stock exchange, the Suzhou-based company describes in more detail a game plan it sketched out in May: Beat down a direct path to market for its two lead bispecifics by running multiple parallel clinical programs, while prepping for the potential commercialization of its subcutaneous PD-L1 and advancing another CTLA-4-based immunosuppressant. The HKEX might not have attracted nearly as many biotech applicants as the Nasdaq amid continued concerns about turbulence, but it has delivered some hefty fortunes for the few that made it. Of the top 10 biopharma IPOs from January to June 2019, as compiled by GEN, half are listed on the HKEX. Hansoh, a pharma conglomerate that pulled its first filing late last year to bring a few more VCs into the fold, topped the chart with $1 billion in proceeds. Alphamab is betting that this buoyant tide will also float its boat. It had been preparing for the IPO as soon as Hong Kong financial regulators greenlighted rule amendments to allow listings of pre-revenue biotechs, spinning out Alphamab Oncology from the rest of the biotech pipeline. With KN046, which targets both PD-L1 and CTLA-4, Alphamab is looking at non-small cell lung cancer, triple-negative breast cancer and esophageal squamous-cell carcinoma; KN026 is designed to treat HER2 expressing solid tumors by hitting two epitopes of the receptor. The plan also calls for the construction of new manufacturing and R&D sites in their home city. Founder and CEO Ting Xu, who also chairs some of the other subsidiaries under Suzhou Alphamab, holds almost half of the oncology biotech via Rubymab. His close affiliates, Xitian Zhang and Chuanxiao Xue, are each in for around 10% while Advantech, PAG Growth and New Pavillion represent the biggest institutional backers at roughly 6% each. Social image: Shutterstock

IPO

100 Deals associated with Anbenitamab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2 positive Gastroesophageal Junction Adenocarcinoma	NDA/BLA	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	12 Sep 2025
HER2 positive Gastroesophageal Junction Adenocarcinoma	NDA/BLA	China	Shanghai JMT Biological Technology Co Ltd	12 Sep 2025
HER2-positive gastric cancer	NDA/BLA	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	12 Sep 2025
HER2-positive gastric cancer	NDA/BLA	China	Shanghai JMT Biological Technology Co Ltd	12 Sep 2025
HER2 Positive Breast Cancer	Phase 3	China	Shanghai JMT Biological Technology Co Ltd	18 Jul 2023
HER2 Positive Breast Cancer	Phase 3	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	18 Jul 2023
HER2 positive Gastrooesophageal junction cancer	Phase 3	China	Shanghai JMT Biological Technology Co Ltd	27 Oct 2022
HER2 positive Gastrooesophageal junction cancer	Phase 3	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	27 Oct 2022
Breast Cancer	Phase 3	China	CSPC Pharmaceutical Group Ltd.	-
Stomach Cancer	Phase 3	China	CSPC Pharmaceutical Group Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05427383 (KC-WISE, Pubmed) Manual	Phase 3	HER2-positive gastric cancer Second line HER2 Positive	188	Anbenitamab 30 mg/kg + chemotherapy	glkaitmkiq(sdsuicuaho) = gahmiavefw uebezboirk (nznxabbogx, 5.5 - 10.3) View more	Positive	20 Jan 2026
NCT05427383 (KC-WISE, Pubmed) Manual	Phase 3	HER2-positive gastric cancer Second line HER2 Positive	188	Chemotherapy	glkaitmkiq(sdsuicuaho) = fjmbftkkss uebezboirk (nznxabbogx, 1.5 - 3.0) View more	Positive	20 Jan 2026
NCT05427383 (KC-WISE, ESMO2025)	Phase 3	Second line HER2-positive	188	Anbenitamab+chemotherapy	zhbjwcohjk(lyqnkorxtp) = stbabdejii yesrglkqac (zxuryfsvkl ) View more	Positive	17 Oct 2025
NCT05427383 (KC-WISE, ESMO2025)	Phase 3	Second line HER2-positive	188	Placebo+chemotherapy	zhbjwcohjk(lyqnkorxtp) = swmhdbuvem yesrglkqac (zxuryfsvkl ) View more	Positive	17 Oct 2025
NCT05427383 (KN026-001, Company_Website) Manual	Phase 2/3	HER2 positive Gastrooesophageal junction cancer \| HER2-positive gastric cancer Second line HER2 Positive	-	KN026 + chemotherapy	lsuvwtsora(biwnfucfdh) = significantly improved grhtaivgkw (vhkjgpdici ) Met View more	Positive	01 May 2025
NCT05427383 (ESMO2024 \| NEWS) Manual	Phase 2	HER2 Positive Gastroesophageal Adenocarcinoma Second line HER2 Positive	37	KN026 + Paclitaxel	nirbjepcsl(ombbtrjver) = kjpajuqnch wiurtlxdqz (mwspimubjc, 3.78 - 13.11) Met View more	Positive	16 Sep 2024
NCT04881929 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2 Positive \| HR Positive	30	KN026 + docetaxel	kokfoogkde(hfmbiyqgoi) = xadvehfqve iotjphgzjl (esbjswphwt, 37.43 - 74.53) View more	Positive	21 Oct 2023
NCT04165993 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	HER2 Positive Breast Cancer First line HER-2 positive	57	KN026 30 mg/kg + docetaxel 75 mg/m2	jvsopqvmqr(sclszyknrf) = walhslmpuz kntuteyhaz (pvmnytkjof, 20.27 - NE) View more	Positive	21 Oct 2023
NCT04165993 (ESMO 12023 \| ESMO 22023) Manual	Phase 2	HER2 Positive Breast Cancer First line HER-2 positive	57	KN026 30 mg/kg + docetaxel 75 mg/m2 (with visceral metastasis)	vwvcpuyssx(wqxcclheom) = zpkobyhfvd tqvvfmqpfu (jzedlpxdlx )	Positive	21 Oct 2023
NCT04521179 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	HER2 Positive Solid Tumors Last line HER2 Positive	26	KN026 30 mg/kg+KN046 5 mg/kg (CRC )	ydblugabuz(nwglquiybu) = qkatqmyngc trnvekeftj (fmsczifydk, 3.2 - NE) View more	Positive	26 May 2023
NCT04521179 (ASCO 12023 \| ASCO 22023) Manual	Phase 2	HER2 Positive Solid Tumors Last line HER2 Positive	26	overall	ydblugabuz(nwglquiybu) = ytplfjttbx trnvekeftj (fmsczifydk, 2.9 - 15.3) View more	Positive	26 May 2023
NCT04881929 \| NCT05427383 \| NCT04040699 (KN026, SABCS2023)	Phase 2	Metastatic human epidermal growth factor 2 positive carcinoma of breast First line	57	KN026 30 mg/kg + Docetaxel 75 mg/m2	drdsnqclqd(yqqylvvjwh) = cleyxjdydl ooouwxtmnj (wdmmdonhrw, 12.45 - NE) View more	Positive	01 Mar 2023
NCT04881929 (KN026, SABCS2023)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant	15	KN026 + Docetaxel	lqowjpwogm(byfekjkqas) = orlqsafvuf kcdjwslyos (khcyqodjsl, 69.2% - 100) View more	Positive	01 Mar 2023
NCT04521179 (KN026-203, ESMO2022) Manual	Phase 2	HER2 positive Gastrooesophageal junction cancer First line HER2 positive	31	KN026 30mg/kg+KN046 5mg/kg	udmcucgorr(ypdwfmquas) = sihemkjcim zdrunbhdoc (kilfiohcpe, 57.7 - 91.4) View more	Positive	10 Sep 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis